News
News

The latest updates from AFAR.

Board Member in the News: David Sinclair on the need for clinical trials to advance age-targeting interventions in WIRED

Dec 19
2017

Board Member in the News: David Sinclair on the need for clinical trials to advance age-targeting interventions in WIRED View MoreBACK

On December 15, 2017, WIRED spotlighted 2000 AFAR Research Grant awardee and current Board Member David Sinclair, PhD, in an article exploring what is advancing—and holding back—Biotech innovations in targeting aging to extend healthspan.

The article, “Silicon Valley’s Immortalists will help Us All Stay Healthy,” surveys lessons learned from promising drug interventions that target the biological processes of aging in order to extend years of health (not to live forever as the piece’s title implies.)

The article notes that without aging being considered an FDA indication, funding for human clinical trials is stalled. Dr. Sinclair shares:

“The aging field is thriving scientifically. But the translation of findings into treatments is poorly funded. Compared to heart disease and diabetes, the dollars allocated to aging are, at best, a hundred to one. But all it will take is one success to change the way people think.”

Dr. Sinclair goes on to list the range of promising can delay age-related illnesses and are poised for clinical trials: ““Super metformin, rapalogs, NAD boosters, mitochondrial activators, senolytics.”

The article also references research and drug interventions led by 2015 Irving S. Wright Award of Distinction winner Leonard Guarente, PhD.

Read the full article in WIRED here.


David Sinclair, PhD is a Professor of Genetics and co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School.





View MoreBACK TO TOP